Drugs / NEO-PTC-01
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04625205 | Dec 2020 → Mar 2025 | metastatic melanoma | BioNTech US Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEO-PTC-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04625205 ↗ |
| Modality | Cell therapy | “NEO-PTC-01 is an autologous personalized T cell (PTC) product for adoptive cell therapy” NCT04625205 ↗ |
| Route | Intravenous | “Administered via intravenous infusion.” NCT04625205 ↗ |